Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has risen over 3%, currently up 3.39% at HKD 9.15, with a trading volume of HKD 297 million [1] Group 1: Company Developments - CSPC Pharmaceutical's wholly-owned subsidiary, CSPC Ouyi Pharmaceutical Co., Ltd., has had its application for the listing of Empagliflozin tablets accepted by the China National Medical Products Administration (NMPA) [1] - Empagliflozin is classified as a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, primarily used for the treatment of type 2 diabetes, heart failure, and chronic kidney disease [1] Group 2: Market Performance - Empagliflozin, developed by Boehringer Ingelheim and co-promoted with Eli Lilly, is one of the three major SGLT-2 inhibitors globally, recognized for its unique glucose-lowering mechanism and cardiovascular and renal protective effects [1] - The sales scale of Empagliflozin tablets in China has rapidly expanded, achieving a milestone of RMB 1 billion in 2024, with a nearly 20% year-on-year growth in the first quarter of 2025 [1]
石药集团涨超3% 恩格列净片上市申请获受理